Pharmacists_ coffee Magazine
Update & develop yourself
Soon: Great opportunity to join pharmacists_ coffee management staff
Magazine site on Facebook
http://www.facebook .com/group. php?gid=62462996 06
To post in pharmacists_ coffee magazine, send to
pharmacists_ coffee@yahoogrou ps.com
Recruitment agencies in UAE
More than 100 recruiters' details
http://health. groups.yahoo. com/group/ Pharmacists_ coffee/files/ Recruitment% 20agencies% 20in%20UAE/
Understand business in Gulf by simple quotes
http://www.freewebs .com/pharmacists /blog.htm? blogentryid= 2973546
English Grammar course
http://health. groups.yahoo. com/group/ Pharmacists_ coffee/files/ English%20Gramma r/
Useful links
http://health. groups.yahoo. com/group/ Pharmacists_ coffee/files/ Useful%20links/
مهارة التعامل مع الآخرين
http://www.freewebs .com/pharmacists /blog.htm? blogentryid= 2974010
كيف تقنع الاخر بوجهه نظرك
http://www.freewebs .com/pharmacists /blog.htm? blogentryid= 2974041
ستـون نصيحه للمسلم في يومه وليلته
http://www.freewebs .com/pharmacists /blog.htm? blogentryid= 2973720
Total Loonier Eclipse of the Moon
From: AMYN <lopm_pbuh@yahoo. com>
Date: Fri Feb 15, 2008 2:26 pm
Subject: Event at our Sky |
|
Salamo Alikom
Dear Friends & Beloved ones. There is a major comic event will happen at the night of Wednesday - Thursday 20-21 of February this year. This event will be the Total Loonier Eclipse of the Moon. For more information about when, where & how see the following link: http://sunearth. gsfc.nasa. gov/eclipse/ LEmono/TLE2008Fe b21/TLE2008Feb21 .html
Don't forget to pray the Eclipse Prayer during that event which become frequent these days & that is one of the signs of the last day.
DrPh.A.M.Y.N
Teaching & Research Assestant
King Saud Uni.-Saudi Arabia
home:(+2)02- 22669365
cell:(+2)010- 5776020 (during July-August only)
cell(KSA):(+ 966)50-8284145
Web Page: AMYN in KSU |
|
شارك في الدفاع عن رسول الله
From: AHMED MOKBEL "™" <abosarwat@yahoo. com>
Date: Sun Feb 17, 2008 12:06 am
Subject: شارك في الدفاع عن رسول الله |
|
شارك في الدفاع عن رسول الله
في مواجهة حملة التشويه الشرسة
أدع كل من تعرف من الأجانب لحضور عرض فيلم "الضباب ينقشع" و المشاركة فى المناقشة المفتوحة (باللغة الإنجليزية) للإجابة على أسئلتهم
www.fogislifting. com
متى: الساعة 7:30 مساء يوم الأحد 24 فبراير
أين: قاعة الكلمة ساقية الصاوى بالزمالك (أسفل كوبرى 15 مايو) |
|
|
|
|
Request
From: pharmacist pharmacist <myresearch_3@ yahoo.com>
Date: Wed Feb 13, 2008 2:11 am
Subject: Request |
|
السلام عليكم
إلى كل الأخوة أعضاء المجموعة
و منهم لهم علاقة بالجامعة الأمريكية بالقاهرة
اود منكم المساعدة فى الحصول على هذه الورقة البحثية Paper
Analytical Chemistry (annali di chimica) Journal
Volume 9 Page 113 (Year 1928)
حاولت الحصول عليها من مكتبة الجامعة الأمريكية
و لكن حالياَ غير متاح لطلاب الماجستير و الدكتوراة من خارج الجامعة الاطلاع و يكون متاح لهم ذلك فى شهر سبتمبر 2008 فى ذلك الوقت تكون الجامعة انتقلت إلى المقر الجديد فى القاهرة الجديدة و حالياً فى احتاج إلى هذه الورقة
أرجو منكم المساعدة |
Pharmaceutical companies' news
Abbott's combo cholesterol drug Simcor approved by FDA
Abbott Laboratories has received approval from US regulators for Simcor, the latest combination drug to be given the go-ahead as a treatment for cholesterol.
Simcor combines Abbott's Niaspan (extended-release niacin) and simvastatin, the active ingredient in Merck & Co's Zocor which came off-patent last year. It targets high-density lipoprotein or `good' cholesterol, as well as low-density lipoprotein `bad' cholesterol plus triglycerides in a single pill.
The green light from the US Food and Drug Administration is based on data from more than 640 patients which demonstrated that patients treated with Simcor enjoyed LDL reductions of 12% and 21% HDL increase compared to a 7% decrease in LDL and an 8% rise in HDL with simvastatin alone. Also the new drug combo reduced triglycerides by 27% compared to 15% with simvastatin alone.
Simcor was generally well tolerated but 6% of patients discontinued therapy due to facial flushing, the most commonly reported side effect of niacin-based therapies. Abbott noted that flushing can be minimised by taking aspirin or a non-steroidal anti-inflammatory drug 30 minutes prior to taking the medication at bedtime. Flushing may subside over several weeks of consistent Simcor, the firm added.
Decision day in the USA for Rotarix imminent for GSK
GlaxoSmithKline is hoping that Rotarix, its rotavirus vaccine, will get the go-ahead from US health regulators this Wednesday after Food and Drug Administration staff posted a fairly positive review on the jab on the agency's website.
The review said that Rotarix appeared to be effective at protecting against rotavirus, the primary cause of severe acute gastroenteritis in young children. However the staffers also expressed concern about data suggesting that the vaccine is associated with an increased risk of pneumonia-related deaths and other adverse events.
US generics makers set out legislative goals for 2008
As US consumers go to the polls "with access to affordable health care at the top of their minds," generics - and biogenerics - "are the solution to reducing health care costs while increasing access to quality care," according to Kathleen Jaeger, chief executive of the US Generic Pharmaceutical Association (GPhA), speaking as its annual conference got underway this week in Florida.
In 2007, generic drugs accounted for a record 65% of the US market, up from 63% the year before, according to new data from IMS Health reported at the meeting. Yesterday, leading US pharmacy benefit manager Express Scripts also noted the fast rise in the use of generics, reporting that their share grew from 40% to 58% of the total US prescription drug market during 2000-2006. The number of US consumers with at least one prescription increased from 57% to 74% over the same period, fueling additional spending of $12 billion for 2006 alone, it says, adding that without generics, that figure would have been much greater. "In fact, greater use of generic drugs still has significant potential for managing prescription drug costs. The key will be using an advanced understanding of the consumer to get more people to choose generics," said Emily Cox, senior director of research at Express Scripts.
Second study shows Avastin as effective in breast cancer
Genentech and majority stakeholder Roche have been boosted by data from a second late-stage trial of Avastin which may help the firm in its bid to get the blockbuster approved as a breast cancer treatment.
The company says that AVADO, a Roche-sponsored Phase III, placebo-controlled study evaluating Avastin (bevacizumab) in combination with docetaxel met its primary endpoint of prolonging progression- free survival in breast cancer patients who had not received prior chemotherapy. The 736-patient study investigated the addition of Avastin administered either at 15 mg/kg or 7.5 mg/kg every three weeks to docetaxel and both doses, in combination with chemotherapy, showed statistically significant improvement in the time patients lived without their disease advancing.
The data is particularly interesting as Genentech is looking to get the green light in the USA for Avastin, which is already approved colorectal and lung cancers, as a treatment for breast cancer in combination with paclitaxel, not docetaxel, the chemotherapy used on the AVADO trial. A Food and Drug Administration decision is expected later this month but Genentech received a setback in December when one of the agency's advisory panels voted 5 to 4 against approval.
Bayer devices unit to buy Possis Medical for $361 million
Bayer has announced plans to acquire the USA 's Possis Medical in a $361 million deal that it will boost its presence in cardiovascular diagnostics.
The acquisition will see Bayer's Medrad medical devices affiliate offer $19.50 per share in cash to take control of Possis, whose board has approved the deal and recommended the offer to shareholders. This represents a premium of 39% over the Minneapolis- based firm's average closing price for the 30 days prior to February 8.
Possis, which posted revenues of $67 million for its fiscal year ended July 31, 2007, has around 280 employees. It specialises in mechanical thrombectomy devices used to treat narrowed or blocked arteries and veins. This makes it a good strategic fit for Medrad which focuses on contrast injection systems to diagnose cardiovascular and other diseases.
The merger "will capitalise on both companies' strengths to deliver growth in our current markets and create a formidable cardiovascular portfolio in the future," said John Friel, chief executive of Medrad, which posted 2006 revenues of $478 million.
